The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease

Behavioural Pharmacology

Volumn 28, Issue 2-3 Special Issue, 2017, Pages 142-160

  Karl, Tim ^a,b   Garner, Brett ^c,d   Cheng, David ^b,e  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WOLLONGONG   (Australia)

^e VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Alzheimer's disease; cannabidiol; cannabinoid receptor; cannabinoids; cognition; dementia; endocannabinoid system; learning and memory; mouse model; therapy

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 LINOLEOYL GLYCEROL; ACETYLCHOLINE; AMYLOID BETA PROTEIN; ANANDAMIDE; CANNABIDIOL; CANNABIMIMETIC; CANNABINOID; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; NABIXIMOLS; NEUROTRANSMITTER; PALMIDROL; PHYTOCANNABINOID; TAU PROTEIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL FUNCTION; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MICROGLIA; NEUROPROTECTION; NONHUMAN; PHENOTYPE; REVIEW; TRANQUILIZING ACTIVITY; ANIMAL; BRAIN; COGNITION; COGNITIVE DEFECT; DRUG EFFECTS; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRAIN; CANNABIDIOL; COGNITION; COGNITION DISORDERS; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 85016062573     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000247     Document Type: Review

References (185)

1. Adams R (1940). Marihuana. Science 92:115-119.
2. Ahmad R, Goffin K, van den Stock J, de Winter FL, Cleeren E, Bormans G, et al. (2014). In vivo type 1 cannabinoid receptor availability in Alzheimers disease. Eur Neuropsychopharmacol 24:242-250.
3. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582-590.
4. Armstrong RA (2013). What causes Alzheimers disease? Folia Neuropathol 51:169-188.
5. Arnold JC, Boucher AA, Karl T (2012). The yin and yang of Cannabis-induced psychosis: the actions of (9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des 18:5113-5130.
6. Aso E, Juves S, Maldonado R, Ferrer I (2013). CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in APP/PS1 mice. J Alzheimers Dis 35:847-858.
7. Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I (2015). Cannabisbased medicine reduces multiple pathological processes in APP/PS1 mice. J Alzheimers Dis 43:977-991.
8. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D (2013). Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci 56:255-262.
9. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, et al. (2012). Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J Neurosci 32:7137-7145.
10. Baruch-Suchodolsky R, Fischer B (2009). Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 48:4354-4370.
11. Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, et al. (2014). Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimers disease. J Alzheimers Dis 40: 701-712.
12. Belbin O, Carrasquillo MM, Crump M, Culley OJ, Hunter TA, Ma L, et al. (2011). Investigation of 15 of the top candidate genes for late-onset Alzheimers disease. Hum Genet 129:273-282.
13. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17:25-30.
14. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31.
15. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimers disease brains. J Neurosci 23:11136-11141.
16. Benito C, Nunez E, Pazos MR, Tolon RM, Romero J (2007). The endocannabinoid system and Alzheimers disease. Mol Neurobiol 36:75-81.
17. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237-249.
18. Bisogno T, Hanus L, de Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845-852.
19. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468.
20. Bitencourt RM, Pamplona FA, Takahashi RN (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849-859.
21. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002). Dose-related neurocognitive effects of marijuana use. Neurology 59:1337-1343.
22. Booz GW (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 51:1054-1061.
23. Brera B, Serrano A, de Ceballos ML (2000). beta-amyloid peptides are cytotoxic to astrocytes in culture: a role for oxidative stress. Neurobiol Dis 7:395-405.
24. Brown AJ (2007). Novel cannabinoid receptors. Br J Pharmacol 152:567-575.
25. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008). CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240-251.
26. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, de Strooper B (2004). Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24:10908-10917.
27. Campbell VA, Gowran A (2007). Alzheimers disease; taking the edge off with cannabinoids? Br J Pharmacol 152:655-662.
28. Campos AC, Palazuelos J, Aguado T, Aguiar DC, Guzman M, GalveRoperh I, Guimaraes FS (2011). Hippocampal proliferative processes are needed for behavioral effects of cannabidiol. Revista de Neurosciencias 19:81.
29. Cardenas A, Moro MA, Hurtado O, Leza JC, Lizasoain I (2005). Dual role of nitric oxide in adult neurogenesis. Brain Res Brain Res Rev 50:1-6.
30. Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103:7895-7900.
31. Casarejos MJ, Perucho J, Gomez A, Munoz MP, Fernandez-Estevez M, Sagredo O, et al. (2013). Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35:525-539.
32. Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W (2010). Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimers disease mouse model. Curr Alzheimer Res 7:255-261.
33. Cheng D, Low JK, Logge W, Garner B, Karl T (2014a). Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1?E9 mice. Psychopharmacology (Berl) 231:3009-3017.
34. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T (2014b). Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimers disease transgenic mice. J Alzheimers Dis 42:1383-1396.
35. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late onset families. Science 261:921-923.
36. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376.
37. DAbramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, et al. (2005). Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391 (Pt 3):693-698.
38. De Ferrari GV, Inestrosa NC (2000). Wnt signaling function in Alzheimers disease. Brain Res Brain Res Rev 33:1-12.
39. De Filippis D, Iuvone T, damico A, Esposito G, Steardo L, Herman AG, et al. (2008). Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 20:919-927.
40. De Lima MN, Polydoro M, Laranja DC, Bonatto F, Bromberg E, Moreira JC, et al. (2005). Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur J Neurosci 21:2521-2528.
41. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ?9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219:859-873.
42. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
43. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:791-802.
44. Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T, et al. (2009). Correlation of iron in the hippocampus with MMSE in patients with Alzheimers disease. J Magn Reson Imaging 29:793-798.
45. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
46. DAddario C, di Francesco A, Arosio B, Gussago C, DellOsso B, Bari M, et al. (2012). Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 7:e39186.
47. DSouza DC (2007). Cannabinoids and psychosis. Int Rev Neurobiol 78: 289-326.
48. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. (2005). Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2:29.
49. Esposito G, de Filippis D, Carnuccio R, Izzo AA, Iuvone T (2006a). The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med 84:253-258.
50. Esposito G, de Filippis D, Maiuri MC, de Stefano D, Carnuccio R, Iuvone T (2006b). Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 399:91-95.
51. Esposito G, Scuderi C, Savani C, Steardo L Jr, de Filippis D, Cottone P, et al. (2007). Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151:1272-1279.
52. Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, de Filippis D, et al. (2011). Cannabidiol reduces A-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR? involvement. PLoS One 6:e28668.
53. Eubanks LM, Rogers CJ, Beuscher AE 4th, Koob GF, Olson AJ, Dickerson TJ, Janda KD (2006). A molecular link between the active component of marijuana and Alzheimers disease pathology. Mol Pharm 3:773-777.
54. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004). Differential effects of THC-or CBD-rich Cannabis extracts on working memory in rats. Neuropharmacology 47:1170-1179.
55. Fagherazzi EV, Garcia VA, Maurmann N, Bervanger T, Halmenschlager LH, Busato SB, et al. (2012). Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berl) 219:1133-1140.
56. Fellermeier M, Eisenreich W, Bacher A, Zenk MH (2001). Biosynthesis of cannabinoids. Incorporation experiments with (13)C-labeled glucoses. Eur J Biochem 268:1596-1604.
57. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
58. Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC (2002). Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 16:1982-1984.
59. Godlewski G, Offertaler L, Wagner JA, Kunos G (2009). Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 89:105-111.
60. Gotz J, Ittner LM (2008). Animal models of Alzheimers disease and frontotemporal dementia. Nat Rev Neurosci 9:532-544.
61. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001). Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495.
62. Gotz J, Ittner LM, Fndrich M, Schonrock N (2008). Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? J Alzheimers Dis 14:423-429.
63. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360.
64. Grotenhermen F (2007). The toxicology of Cannabis and Cannabis prohibition. Chem Biodivers 4:1744-1769.
65. Gschwind M, Huber G (1995). Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. J Neurochem 65:292-300.
66. Haas J, Storch-Hagenlocher B, Biessmann A, Wildemann B (2002). Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimers dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci Lett 322:121-125.
67. Hallak JE, Dursun SM, Bosi DC, de Macedo LR, Machado-de-Sousa JP, Abro J, et al. (2011). The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 35:198-202.
68. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998). Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273.
69. Harvey DJ, Samara E, Mechoulam R (1991). Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav 40:523-532.
70. Harvey BS, Ohlsson KS, Maag JL, Musgrave IF, Smid SD (2012). Contrasting protective effects of cannabinoids against oxidative stress and amyloid-evoked neurotoxicity in vitro. Neurotoxicology 33:138-146.
71. Henstridge CM (2012). Off-target cannabinoid effects mediated by GPR55. Pharmacology 89:179-187.
72. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
73. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG (2011). Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 163:1329-1343.
74. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
75. Iuvone T, Esposito G, Esposito R, Santamaria R, di Rosa M, Izzo AA (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 89:134-141.
76. Iuvone T, Esposito G, de Filippis D, Scuderi C, Steardo L (2009). Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15: 65-75.
77. Izzo AA, Borrelli F, Capasso R, di Marzo V, Mechoulam R (2009). Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515-527.
78. Janefjord E, Maag JL, Harvey BS, Smid SD (2014). Cannabinoid effects on amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell Mol Neurobiol 34:31-42.
79. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
80. Jones RT (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol 42:58S-63S.
81. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, et al. (2012). An amyloid 42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimers disease. Neurobiol Aging 33 :1522-1532.
82. Kalifa S, Polston EK, Allard JS, Manaye KF (2011). Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1 E9 double transgenic mice. Brain Res 1376:94-100.
83. Kamboh MI (2004). Molecular genetics of late-onset Alzheimers disease. Ann Hum Genet 68 (Pt 4):381-404.
84. Karl T, Cheng D, Garner B, Arnold JC (2012). The therapeutic potential of the endocannabinoid system for Alzheimers disease. Expert Opin Ther Targets 16:407-420.
85. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172-177.
86. Kathmann M, Flau K, Redmer A, Trnkle C, Schlicker E (2006). Cannabidiol is an allosteric modulator at mu-and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372:354-361.
87. Kitamura Y, Shimohama S, Koike H, Ji Kakimura, Matsuoka Y, Nomura Y, et al. (1999). Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimers disease brains. Biochem Biophys Res Commun 254:582-586.
88. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, et al. (2011). Cannabidiol potentiates ?9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 218:443-457.
89. Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, et al. (2009). Endocannabinoids in Alzheimers disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8:2.
90. Krause DL, Muller N (2010). Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimers disease. Int J Alzheimers Dis 2010. doi: 10.4061/2010/732806.
91. Kuret J, Chirita CN, Congdon EE, Kannanayakal T, Li G, Necula M, et al. (2005). Pathways of tau fibrillization. Biochim Biophys Acta 1739:167-178.
92. Lambert DM, Fowler CJ (2005). The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48: 5059-5087.
93. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, et al. (2010). Intact cannabinoid CB1 receptors in the Alzheimers disease cortex. Neurochem Int 57:985-989.
94. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav 66:175-181.
95. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94.
96. Lichtman AH, Dimen KR, Martin BR (1995). Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282-290.
97. Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A, et al. (2005).Wnt signalling regulates adult hippocampal neurogenesis. Nature 437: 1370-1375.
98. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-19.
99. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E (2003). Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 93:377-387.
100. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010). A behavioural comparison of acute and chronic delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13: 861-876.
101. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316:780-788.
102. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM (2009). Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 51:528-534.
103. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 159:950-957.
104. Mahler SV, Smith KS, Berridge KC (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances liking of a sweet reward. Neuropsychopharmacology 32:2267-2278.
105. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, et al. (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139-1141.
106. Mallet P, Beninger R (1996). The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav Pharmacol 7:276-284.
107. Marchalant Y, Brothers HM, Wenk GL (2008). Inflammation and aging: can endocannabinoids help? Biomed Pharmacother 62:212-217.
108. Marchesi VT (2011). Alzheimers dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25:5-13.
109. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13:951-957.
110. Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers disease. Mol Pharmacol 79:964-973.
111. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, et al. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9:8.
112. Mattson MP (2002). Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimers disease. J Neurovirol 8:539-550.
113. Mazzola C, Micale V, Drago F (2003). Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477:219-225.
114. McGeer PL, McGeer EG (2015). Targeting microglia for the treatment of Alzheimers disease. Expert Opin Ther Targets 19:497-506.
115. McHugh D (2012). GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol 167:1575-1582.
116. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, Bradshaw HB (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11:44.
117. McPartland JM, Duncan M, di Marzo V, Pertwee RG (2015). Are cannabidiol and (9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737-753.
118. Mechoulam R, Gaoni Y (1965). A total synthesis of Dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273-3275.
119. Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11s-19s.
120. Micale V, Mazzola C, Drago F (2007). Endocannabinoids and neurodegenerative diseases. Pharmacol Res 56:382-392.
121. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, et al. (2011). Molecular reorganization of endocannabinoid signalling in Alzheimers disease. Brain 134 (Pt 4):1041-1060.
122. Nslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
123. Nicholson DW, Thornberry NA (1997). Caspases: killer proteases. Trends Biochem Sci 22:299-306.
124. Nilsson M, Hansson S, Carlsson A, Carlsson ML (2007). Differential effects of the N-methyl-D-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience 149:123-130.
125. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279:5298-5305.
126. Pacher P, Mechoulam R (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193-211.
127. Paradisi A, Oddi S, Maccarrone M (2006). The endocannabinoid system in ageing: a new target for drug development. Curr Drug Targets 7:1539-1552.
128. Parsons CG, Danysz W, Dekundy A, Pulte I (2013). Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimers disease. Neurotox Res 24:358-369.
129. Pascual AC, Martin-Moreno AM, Giusto NM, de Ceballos ML, Pasquare SJ (2014). Normal aging in rats and pathological aging in human Alzheimers disease decrease FAAH activity: modulation by cannabinoid agonists. Exp Gerontol 60:92-99.
130. Passmore MJ (2008). The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry 23:116-117.
131. Perry VH, Nicoll JA, Holmes C (2010). Microglia in neurodegenerative disease. Nat Rev Neurol 6:193-201.
132. Pertwee RG (2004). The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V, editor. Cannabinoids. New York, NY: Kluwer Academic/ Plenum Publishers. pp. 1-52.
133. Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
134. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199-215.
135. Pertwee RG, Ross RA, Craib SJ, Thomas A (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99-106.
136. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:PL1-PL6.
137. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimers disease amyloid-beta peptides. Nature 423:435-439.
138. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
139. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M (2015). World Alzheimer Report 2015. The Global Impact of Dementia. London: Alzheimer's Disease International.
140. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005). Prevention of Alzheimers disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25:1904-1913.
141. Russo EB (2011). Taming THC: potential Cannabis synergy and phytocannabinoidterpenoid entourage effects. Br J Pharmacol 163:1344-1364.
142. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037-1043.
143. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101.
144. Satoh J, Kuroda Y (2000). Amyloid precursor protein beta-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology 20:289-296.
145. Schliebs R, Arendt T (2011). The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555-563.
146. Schneider U, Borsutzky M, Seifert J, Leweke FM, Huber TJ, Rollnik JD, Emrich HM (2002). Reduced binocular depth inversion in schizophrenic patients. Schizophr Res 53:101-108.
147. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, et al. (2008). Memantine leads to behavioral improvement and amyloid reduction in Alzheimers-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86:2784-2791.
148. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23:597-602.
149. Scuderi C, Steardo L, Esposito G (2014). Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP + cells through PPAR? involvement. Phytother Res 28:1007-1013.
150. Solas M, Francis PT, Franco R, Ramirez MJ (2013). CB2 receptor and amyloid pathology in frontal cortex of Alzheimers disease patients. Neurobiol Aging 34:805-808.
151. Solowij N, Broyd SJ, van Hell HH, Hazekamp A (2014). A protocol for the delivery of cannabidiol (CBD) and combined CBD and 9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 15:58.
152. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. (2010). The Alzheimers disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5:e9505.
153. Sperber BR, Leight S, Goedert M, Lee VM (1995). Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 197:149-153.
154. Stella N (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:1017-1030.
155. Stella N, Schweitzer P, Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778.
156. Stern CA, Gazarini L, Takahashi RN, Guimares FS, Bertoglio LJ (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 37:2132-2142.
157. Streit WJ (2004). Microglia and Alzheimers disease pathogenesis. J Neurosci Res 77:1-8.
158. Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, et al. (2013). Cannabinoid receptor 1 deficiency in a mouse model of Alzheimers disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol Aging 34:2574-2584.
159. Takeuchi H (2010). Neurotoxicity by microglia: Mechanisms and potential therapeutic strategy. Clin Exp Immunol 1:12-21.
160. Tanasescu R, Constantinescu CS (2010). Cannabinoids and the immune system: an overview. Immunobiology 215:588-597.
161. Teng L, Zhao J, Wang F, Ma L, Pei G (2010). A GPCR/secretase complex regulates beta-and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell Res 20:138-153.
162. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285:285-292.
163. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613-623.
164. Tolon RM, Nunez E, Pazos MR, Benito C, Castillo AI, Martinez-Orgado JA, Romero J (2009). The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 1283:148-154.
165. Umeda T, Mori H, Zheng H, Tomiyama T (2010). Regulation of cholesterol efflux by amyloid beta secretion. J Neurosci Res 88:1985-1994.
166. Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, de Filippis D, et al. (2006). Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63:1410-1424.
167. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, Martin BR (2006). Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 186:226-234.
168. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimers disease. Int J Geriatr Psychiatry 12:913-919.
169. Wade DT, Collin C, Stott C, Duncombe P (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707-714.
170. Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141:775-785.
171. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405.
172. Walther S, Mahlberg R, Eichmann U, Kunz D (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 185:524-528.
173. Walther S, Schupbach B, Seifritz E, Homan P, Strik W (2011). Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 31:256-258.
174. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996). Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109-1111.
175. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994). Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimers brains. Neuroscience 63:637-652.
176. Winsauer PJ, Lambert P, Moerschbaecher JM (1999). Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol 10:497-511.
177. Wolf SA, Bick-Sander A, Fabel K, Leal-Galicia P, Tauber S, Ramirez-Rodriguez G, et al. (2010). Cannabinoid receptor CB1 mediates baseline and activityinduced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 8:12.
178. Wolfe MS (2009). Tau mutations in neurodegenerative diseases. J Biol Chem 284:6021-6025.
179. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M (2013). Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging 34:791-804.
180. Zandi PP, Breitner JC (2001). Do NSAIDs prevent Alzheimers disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22: 811-817.
181. Zandi PP, Breitner JC, Anthony JC (2002). Is pharmacological prevention of Alzheimers a realistic goal? Expert Opin Pharmacother 3:365-380.
182. Zuardi AW, Karniol IG (1983). Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Braz J Med Biol Res 16:141-146.
183. Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG (1981). Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 249:137-146.
184. Zuardi AW, Rodrigues JA, Cunha JM (1991). Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 104:260-264.
185. Zuardi AW, Morais SL, Guimares FS, Mechoulam R (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry 56:485-486.